The biotech teaching the immune system to see the ancient viruses hidden inside our own DNA.
Roughly 8% of the human genome is not, strictly speaking, human. It is viral - the fossilized remains of retroviruses that infected our ancestors and wrote themselves permanently into our DNA. These sequences, called human endogenous retroviruses, or HERVs, usually sit silent. HERVolution Therapeutics is built on the idea that when they wake up, they help drive disease.
HERVolution is a clinical-stage biotechnology company, based in Frederiksberg on the edge of Copenhagen, developing immunotherapies that target these HERVs. The company works in what researchers call the "dark genome" - the vast, long-ignored, non-coding stretches of our DNA. HERVs typically stay dormant when a person is young and healthy, but can reactivate with age or disease, where the company says they amplify aging and contribute to the progression of cancer, type 2 diabetes, and certain neurodegenerative conditions.
The technical problem is that these antigens are, biologically speaking, "self." The immune system has been trained since birth to ignore them. HERVolution's proprietary protein-engineering platform rationally redesigns HERV antigens to break that tolerance - making the once-invisible visible. The company says it has demonstrated human immune-cell activation toward HERVs for the first time.
We have broken human immune tolerance to HERVs, enabling therapeutic targeting for the first time.J. Robert Coleman, PhD, MBA - Chairman & CEO
The approach reads less like a single drug and more like a strategy for a whole antigen class. Instead of chasing one mutation in one tumor, HERVolution points at a target that shows up across many diseases of aging.
Identify HERV antigens in the dark genome that reactivate during aging, cancer, or metabolic stress.
Rationally re-engineer the antigen so the immune system no longer treats it as harmless "self."
Package it in vectors - adenoviral (IPT-001) and mRNA (IPT-002) - to prime and boost a targeted response.
Trigger HERV-specific T and B cell activity, turning an invisible target into a treatable one.
HERVolution's assets are designed to be "off-the-shelf" - manufacturable, vector-based products rather than bespoke therapies made one patient at a time. That engineering choice matters: it is part of why a manufacturing giant like the Serum Institute of India took an interest.
| Program | Type | Focus | Stage |
|---|---|---|---|
| IPT-001 | Dual adenoviral vector | Oncology & metabolic disease | Advancing toward first-in-human |
| IPT-002 | mRNA vector (HERV antigen) | Prime-boost & maintenance dosing | Preclinical |
| Metabolic program | Insulin-sensitization immune therapy | Obesity / weight control | Preclinical proof-of-concept (2026) |
| Platform | Dark genome / HERV engineering | Cancer, metabolic, aging, neuro | Core technology |
HERVolution sits at the intersection of three crowded fields - immuno-oncology, metabolic disease, and longevity - but reaches them through an unusual door. Most immunotherapy companies hunt for new targets on the surface of tumors or design personalized neoantigen vaccines. HERVolution instead treats a hidden mechanism it believes is shared across many diseases of aging.
Its closest peers are other "dark genome" and endogenous-retrovirus players such as ROME Therapeutics and Enara Bio, alongside the broader universe of cancer vaccine, senescence, and metabolic-disease biotechs. The differentiators HERVolution leans on: a tolerance-breaking platform, off-the-shelf vector assets, and one target class that spans oncology, diabetes, obesity, and neurodegeneration.
As a preclinical/early-clinical company, HERVolution has no commercial customers yet. Its ultimate beneficiaries are patients with cancer, type 2 diabetes, obesity-related disease, and other conditions of aging. Its near-term stakeholders are strategic partners, academic collaborators, and investors.
Venture and strategic investment, non-dilutive grants such as the EIC Fund, and partnership/licensing deals fund R&D. Value is created by advancing off-the-shelf assets through the clinic toward licensing or commercialization with pharma and manufacturing partners.
PhD virologist and serial biotech builder. Co-founded Codagenix, where he helped secure up to roughly $498M for viral-based vaccines and therapeutics. BS from Tulane, PhD from Stony Brook, MBA from NYIT. Joined HERVolution as CEO in December 2023.
MD, PhD and scientific founder of the company (formerly InProTher). Architect of the HERV-targeting and vaccine-vector science that underpins the platform.
Serum Institute of India (lead investor and development partner), European Innovation Council Fund, and research collaborators at the University of Copenhagen and Bispebjerg-Frederiksberg Hospital.
This financing represents a significant milestone for the company and signals strong support.Peter Holst, MD, PhD - Founder & Chief Scientific Officer
The company rebrands around its HERV focus and appoints J. Robert Coleman as chief executive in December.
The Serum Institute of India leads the round, with European Innovation Council Fund participation, to advance IPT-001 and IPT-002 toward the clinic.
HERVolution reports preclinical proof-of-concept for an insulin-sensitization therapy and licenses HERV weight-control technology from the University of Copenhagen.
Presents data linking HERV-K reactivation to metabolic senescence at the International Congress on Obesity in Mexico City.
Video: no official YouTube channel or product-demo video was found at time of writing. Search "HERVolution Therapeutics" or "J. Robert Coleman dark genome" on YouTube for conference talks and interviews.